What changed from existing technology?
This study looked at how well early warning signs for HIV drug resistance work in Lesotho when using a new HIV drug called dolutegravir, and what factors affect their effectiveness.
This study is the first to evaluate the performance of WHO-recommended HIVDR Early Warning Indicators in the context of dolutegravir-based treatment programs in a low-resource setting like Lesotho.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 3
utegravir (DTG)-based regimens have improved treatment durability, programmatic factors such as poor adherence, treatment interruptions, and inadequate monitori
Abstract ↗ING THE DOLUTEGRAVIR ERA. HIV drug resistance (HIVDR) remains a major threat to the long-term effectiveness of antiretroviral therapy (ART) programs, par
Abstract ↗OpenAlex author affiliations: Living Systems (United States)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings could help improve monitoring systems for HIV drug resistance in resource-limited settings by identifying factors that influence the effectiveness of early warning indicators.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchPERFORMANCE OF HIV DRUG RESISTANCE EARLY WARNING INDICATORS AND ASSOCIATED PROGRAM FACTORS IN LESOTHO DURING THE DOLUTEGRAVIR ERAResearch · Published 2026-09-09 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.